Children's National Medical Center
Washington, District of Columbia, United States
Miriam Bornhorst, MD has a joint appointment at George Washington University Hospital and Children’s National Hospital (CNH) in Washington D.C. Dr. Bornhorst’s main clinical interests are cancer predisposition (including Neurofibromatosis) and Neuro-Oncology. She is the Medical Director of the Cancer Genetics Clinic and Clinical director of the Gilbert Neurofibromatosis Program at CNH. Dr. Bornhorst is the institution PI for multiple clinical trials for patients with NF1 at CNH, including clinical trials of MEK-inhibitors. Her research focuses on early detection and treatment of patients at risk for developing cancer - ultimately improving long term outcomes. She is currently studying how MEK-inhibitor treatment affects metabolism in children with NF1, with the goal to identify biomarkers that can be used to predict response to treatment, as well as gain a better understanding of how diet affects tumor growth. She is also investigating novel and low allele fraction genomic changes within NF-associated tumors using optical genome mapping.
